Activated protein C resistance test using factor VIII-deficient plasma: A new approach to the venous thrombotic risk? [6]

Thrombosis and Haemostasis

Volumn 98, Issue 3, 2007, Pages 693-694

  André, Elisabeth ^a   Hacquard, Marie ^a,b   Alnot, Yveline ^a   de Maistre, Emmanuel ^a   Lecompte, Thomas ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8;

ACTIVATED PROTEIN C RESISTANCE; BLOOD SAMPLING; CENTRIFUGATION; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE POOR PLASMA; VEIN PUNCTURE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOLUNTEER;

ACTIVATED PROTEIN C RESISTANCE; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FEMALE; HEMOPHILIA A; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34548676176     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-11-0661     Document Type: Letter

References (13)

1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C : prediction of a cofacteur to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
2. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
3. Jorquera JI, Montoto JM, Fernandez MA, et al. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
4. Guerrero F, Arnaud C, Nguyen F, et al. Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non carriers of the factor V Leiden mutation. Tbromb Haemost 2006; 95: 728-734.
5. Regnault V, De Maistre E, Geshier C, et al. A new fastone-step inummopreparation for activated protein C. Thromb Haemost 1995; 73: 1780.
6. Henkens C, Born V, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1197-1207.
7. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
8. Kraaijenhagen RA, Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc: is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
9. O'Donnell J, Mumford AD, Mannig RA, et al. Elevation of FVIII :C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-13.
10. Soria JM, Almasy L, Souto JC, et al. A new locus on chromosome 18 that influences normal variant in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003; 101: 163-167.
11. Nossent AY, Eikenboom JC, Vos HL, et al. Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. Thromb Haemost 2006; 95: 942-948.
12. Roelse JC, Foopman M, Buller HR, et al. Absence of mutations at the activated protein C cleavage site of factor VIII in 125 patients with venous thrombosis. Brit J Haematol 1996; 92: 740-743.
13. Brummer J, Groth J, Flayeh F, et al. Absence of mutations at the APC interacting sites of factor VIII in Caucasians. Thromb Haemost 2002; 87: 170-171.